We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Website: https://members.lesusacanada.org/events/EventDetails.aspx?id=1568597&group=
In September of 2021, India and South Africa proposed to suspend global intellectual property rights under the Trade Related Aspects of Intellectual Property Right (TRIPS) Agreement in relation to products or processes to treat, prevent, or diagnose Covid-19. The offered justifications include: (1) waiving global IP could mobilize additional available vaccine manufacturing capacity around the world; (2) existing internationally-agreed procedures for compulsory licensing of IP under the TRIPS Agreement are too slow, cumbersome, and inefficient in the current pandemic; (3) Covid vaccine and therapeutic technology was created with the help of public funding and should be freely available in the public domain; (4) existing manufacturing capacity is controlled by a few profit-driven corporations that cannot be trusted to work in the public interest and are selling their vaccine output to the highest-bidding rich countries.
This program will explore the scope of the proposed Waiver, the status of discussions in the WTO and domestically in the US, and the implications of waiving global IP rights for current and future pandemic preparedness, US competitiveness, and global trade.
This event is FREE to LES Members. (LES International Members - please contact info@les.org for a code)
